Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's Laboratories enters into a Voluntary Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment
This is for your information.
| With regards, | |
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. | Investor relationS AMIT AgARWAL amita@drreddys.com (Ph: +91-98661 74248) | Media relationS Usha IYER ushaiyer@drreddys.com (Ph: + 91-99874 44106) |
Dr. Reddy's Laboratories enters into a Voluntary Licensing
Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Hyderabad, India, May 11th, 2021
Hyderabad, India. May 11, 2021- Dr.
Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as "Dr. Reddy's")
today announced that it has entered into a royalty-free, non-exclusive voluntary licensing agreement with Eli Lilly and Company
("Lilly") for the manufacture and commercialization of the drug, baricitinib, in India.
The drug baricitinib has received restricted
emergency use approval from the Central Drugs Standard Control Organization (CDSCO), Ministry of Health, India, for use in combination
with remdesivir for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults requiring supplemental oxygen,
invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).
This partnership comes at a critical juncture
in the fight against the pandemic in India, and adds to the company's existing range of COVID-19 therapeutics covering the
full spectrum from mild to moderate and severe conditions of the disease, and a vaccine.
Deepak Sapra, Chief Executive Officer,
API and Services, Dr. Reddy's Laboratories, said: "From the start, we have been determined to explore every possible
avenue against COVID-19. Our collaboration with Lilly will help us make yet another treatment option available to patients in India."
About Dr. Reddy's: Dr. Reddy's
Laboratories Ltd. ((BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company, committed
to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services &
Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas
of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy's operates
in markets across the globe. Our major markets include - USA, India, Russia & CIS countries, and Europe. For more information,
log on to: www.drreddys.com
Disclaimer: This press release may include statements of future
expectations and other forward-looking statements that are based on the management's current views and assumptions and involve
known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those
expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",
"will", "should", "expects", "plans", "intends", "anticipates", "believes",
"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking
statements. Actual results, performance or events may differ materially from those in such statements due to without limitation,
(i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates,
persistency levels and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing
levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks
and/or governments, (v) the impact of acquisitions or reorganization, including related integration issues,and (vi) the
susceptibility of our industry and the markets addressed by our, and our customers', products and services to economic downturns
as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus (or COVID-19), and (vii)
other risks and uncertainties identified in our public filings with the Securities and Exchange Commission, including those listed
under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report on Form 20-F for the
year ended March 31, 2020. The company assumes no obligation to update any information contained herein."